# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Scholar Rock stock falls as FDA issues Form 483 to Catalent; company to meet FDA, while apitegromab shows lean mass preservatio...
https://scholarrock.com/our-company/newsroom/update-on-third-party-manufacturing-site/
B of A Securities analyst Tazeen Ahmad initiates coverage on Scholar Rock Holding (NASDAQ:SRRK) with a Buy rating and announ...
U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Friday. Shares of Crinetics Pharmaceutical...
Piper Sandler analyst Allison Bratzel maintains Scholar Rock Holding (NASDAQ:SRRK) with a Overweight and lowers the price ta...